Individualized Multimodal Hemostasis Evaluation Pyramid (IMHOTEP)

CompletedOBSERVATIONAL
Enrollment

59

Participants

Timeline

Start Date

August 1, 2017

Primary Completion Date

August 1, 2020

Study Completion Date

August 31, 2020

Conditions
Blood Loss, PostoperativeLiver TransplantHemostatic Disorder
Interventions
DIAGNOSTIC_TEST

Coagulation factor levels

The minimal functional hemostasis reserve capacity are defined by triggers as hematocrit: 27%, platelets: 30 G/l, Fibrinogen (FI): 1g/l, FII-FV-FVII-FX: 30%, Antithrombin III: 40%, FXIII: 60% levels. The estimate blood volume methodology is used for to determine the amount of allowable blood loss in volume (ml) that does not require replacement based on current and trigger levels. The individualized pyramid of intervention defined as hemostasis reserve capacity are followed at every studied patient. All measurements and calculations are performed before liver transplantation (T1), at arrival on Intensive Care Unit (T2) and 12-24-48 hours after liver transplantation (T3-4-5).

Trial Locations (1)

1082

Semmelweis University, Budapest

All Listed Sponsors
lead

Semmelweis University

OTHER

NCT03555383 - Individualized Multimodal Hemostasis Evaluation Pyramid (IMHOTEP) | Biotech Hunter | Biotech Hunter